Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.

Williams L, Tucker TA, Koenig K, Allen T, Rao LV, Pendurthi U, Idell S.

Am J Respir Cell Mol Biol. 2012 Feb;46(2):173-9. doi: 10.1165/rcmb.2010-0276OC. Epub 2011 Aug 18.

2.

The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.

Tucker TA, Dean C, Komissarov AA, Koenig K, Mazar AP, Pendurthi U, Allen T, Idell S.

Am J Respir Cell Mol Biol. 2010 Jun;42(6):685-96. doi: 10.1165/rcmb.2008-0433OC. Epub 2009 Jul 27.

3.

Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells.

Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S.

Eur Respir J. 2000 Jun;15(6):1069-78.

4.

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS.

Clin Cancer Res. 2012 May 1;18(9):2478-89. doi: 10.1158/1078-0432.CCR-11-2614. Epub 2012 Feb 27.

5.

Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.

Keshava S, Sahoo S, Tucker TA, Idell S, Rao LV, Pendurthi UR.

Cancer Res. 2013 Jul 1;73(13):3963-73. doi: 10.1158/0008-5472.CAN-12-1690. Epub 2013 Mar 28.

7.

Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.

Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.

Int J Cancer. 2011 Aug 15;129(4):1005-17. doi: 10.1002/ijc.25716. Epub 2010 Dec 2.

8.

Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.

Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM.

Cancer Res. 2003 Aug 1;63(15):4547-51.

9.

SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.

Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.

Int J Cancer. 2013 Jan 15;132(2):459-71. doi: 10.1002/ijc.27611. Epub 2012 May 17.

10.

Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.

Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB.

Oncol Res. 1999;11(4):187-94.

PMID:
10566617
11.

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N.

Ann Oncol. 2013 Dec;24(12):3128-35. doi: 10.1093/annonc/mdt412. Epub 2013 Oct 22.

12.

E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.

Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S.

Clin Cancer Res. 2009 Dec 1;15(23):7229-37. doi: 10.1158/1078-0432.CCR-09-1980. Epub 2009 Nov 24.

13.

Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.

Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC.

Int J Oncol. 2006 Jul;29(1):25-32.

14.

Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.

Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S.

Am J Pathol. 2011 Sep;179(3):1483-93. doi: 10.1016/j.ajpath.2011.05.060. Epub 2011 Jul 18.

15.

Gli as a novel therapeutic target in malignant pleural mesothelioma.

Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B.

PLoS One. 2013;8(3):e57346. doi: 10.1371/journal.pone.0057346. Epub 2013 Mar 6.

16.

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.

Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K.

Int J Cancer. 2010 Oct 15;127(8):1948-57. doi: 10.1002/ijc.25197.

17.

Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.

Cioce M, Canino C, Pulito C, Muti P, Strano S, Blandino G.

Cell Cycle. 2012 Jan 1;11(1):132-40. doi: 10.4161/cc.11.1.18474. Epub 2012 Jan 1.

PMID:
22185775
18.

Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.

Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S.

Cancer Sci. 2006 Mar;97(3):183-91.

19.

Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.

Volta V, Ranzato E, Martinotti S, Gallo S, Russo MV, Mutti L, Biffo S, Burlando B.

PLoS One. 2013;8(3):e58051. doi: 10.1371/journal.pone.0058051. Epub 2013 Mar 6.

20.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

PMID:
24094913
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk